138 related articles for article (PubMed ID: 37317924)
1. Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model.
Kloos RQH; Mathôt R; Pieters R; Van der Sluis IM
Haematologica; 2023 Sep; 108(9):2558. PubMed ID: 37317924
[No Abstract] [Full Text] [Related]
2. Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model.
Kloos RQH; Mathôt R; Pieters R; van der Sluis IM
Haematologica; 2021 May; 106(5):1254-1261. PubMed ID: 32327497
[TBL] [Abstract][Full Text] [Related]
3. Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Kloos RQH; Pieters R; Jumelet FMV; de Groot-Kruseman HA; van den Bos C; van der Sluis IM
J Clin Oncol; 2020 Mar; 38(7):715-724. PubMed ID: 31922920
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia.
Brigitha LJ; Mondelaers V; Liu Y; Albertsen BK; Zalewska-Szewczyk B; Rizzari C; Kotecha RS; Pieters R; Huitema ADR; van der Sluis IM
Pharm Res; 2024 Apr; 41(4):711-720. PubMed ID: 38538970
[TBL] [Abstract][Full Text] [Related]
5. Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group.
Brigitha LJ; Fiocco M; Pieters R; Albertsen BK; Escherich G; Lopez-Lopez E; Mondelaers V; Vora A; Vrooman L; Schmiegelow K; van der Sluis IM;
Eur J Cancer; 2022 Feb; 162():65-75. PubMed ID: 34954438
[TBL] [Abstract][Full Text] [Related]
6. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.
Tong WH; Pieters R; Kaspers GJ; te Loo DM; Bierings MB; van den Bos C; Kollen WJ; Hop WC; Lanvers-Kaminsky C; Relling MV; Tissing WJ; van der Sluis IM
Blood; 2014 Mar; 123(13):2026-33. PubMed ID: 24449211
[TBL] [Abstract][Full Text] [Related]
7. Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy.
Tong WH; van der Sluis IM; Alleman CJ; van Litsenburg RR; Kaspers GJ; Pieters R; Uyl-de Groot CA
Haematologica; 2013 May; 98(5):753-9. PubMed ID: 23403311
[TBL] [Abstract][Full Text] [Related]
8. A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia.
Kloos RQH; Uyl-de Groot CA; van Litsenburg RRL; Kaspers GJL; Pieters R; van der Sluis IM
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28766887
[TBL] [Abstract][Full Text] [Related]
9. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia.
Aldoss I; Douer D
Blood; 2020 Mar; 135(13):987-995. PubMed ID: 31977001
[TBL] [Abstract][Full Text] [Related]
10. Native E. coli asparaginase upfront should be replaced by PEGasparaginase upfront in the treatment of pediatric patients with acute lymphoblastic leukemia.
Tong WH; Mesegué M; Dapena JL; Camós M; Rives S
Hematol Oncol; 2022 Oct; 40(4):809-811. PubMed ID: 34961954
[No Abstract] [Full Text] [Related]
11. The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
Tong WH; Pieters R; de Groot-Kruseman HA; Hop WC; Boos J; Tissing WJ; van der Sluis IM
Haematologica; 2014 Nov; 99(11):1716-21. PubMed ID: 25150254
[TBL] [Abstract][Full Text] [Related]
12. Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker.
Kloos R; van der Sluis IM; Mastrobattista E; Hennink W; Pieters R; Verhoef JJ
Br J Haematol; 2020 May; 189(3):442-451. PubMed ID: 31883112
[TBL] [Abstract][Full Text] [Related]
13. Depletion of d- and l-asparagine in cerebrospinal fluid in acute lymphoblastic leukemia during PEGasparaginase therapy.
Brigitha LJ; Pieters R; Struys EA; Bakkali A; van der Sluis IM
Pediatr Blood Cancer; 2022 Nov; 69(11):e29865. PubMed ID: 35880973
[TBL] [Abstract][Full Text] [Related]
14. Desensitization protocol should not be used in acute lymphoblastic leukemia patients with silent inactivation of PEGasparaginase.
Tong WH; Pieters R; Tissing WJ; van der Sluis IM
Haematologica; 2014 Jul; 99(7):e102-4. PubMed ID: 24682510
[No Abstract] [Full Text] [Related]
15. SOHO State of the Art Updates and Next Questions | Asparaginase-Understanding and Overcoming Toxicities in Adults with ALL.
Aldoss I; Pourhassan H; Douer D
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):787-794. PubMed ID: 36114134
[TBL] [Abstract][Full Text] [Related]
16. Pegasparaginase treatment alters thrombin generation by modulating the protein C and S system in acute lymphoblastic leukaemia/lymphoma.
Staddon JH; Smock KJ; Schiffman JD; Fluchel MN; Engel ME; Weyrich AS; Campbell RA
Blood Coagul Fibrinolysis; 2015 Oct; 26(7):840-3. PubMed ID: 26196196
[TBL] [Abstract][Full Text] [Related]
17. Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.
Bade NA; Lu C; Patzke CL; Baer MR; Duong VH; Law JY; Lee ST; Sausville EA; Zimrin AB; Duffy AP; Lawson J; Emadi A
J Oncol Pharm Pract; 2020 Jan; 26(1):74-92. PubMed ID: 30917738
[TBL] [Abstract][Full Text] [Related]
18. Comment on: Desensitization using PEGasparaginase in the era of commercially available Erwinia: A single-institution report on efficacy, cost, and resource utilization.
Tong WH
Pediatr Blood Cancer; 2024 May; 71(5):e30935. PubMed ID: 38433328
[No Abstract] [Full Text] [Related]
19. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.
Stock W; Douer D; DeAngelo DJ; Arellano M; Advani A; Damon L; Kovacsovics T; Litzow M; Rytting M; Borthakur G; Bleyer A
Leuk Lymphoma; 2011 Dec; 52(12):2237-53. PubMed ID: 21827361
[TBL] [Abstract][Full Text] [Related]
20. Comment on "Comparison of hypersensitivity rates to intravenous and intramuscular PEGasparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review".
Tong WH
Pediatr Blood Cancer; 2021 Dec; 68(12):e29250. PubMed ID: 34288392
[No Abstract] [Full Text] [Related]
[Next] [New Search]
